SCIENTISTS at the University of Sydney, Australia have been awarded $1.7m from NSW Health, to research a new treatment for chronic pain affecting people with spinal cord injuries, BioSpectrum has reported.
Up to 80% of people with a spinal cord injury develop some degree of persistent pain.
Recent research by the National Drug Strategy Household Survey found 2.7% of the country's population took up cannabis use for medicinal purposes in 2019 - a figure which has been rapidly rising since the drug was made available via prescription in late 2016.
In partnership with the Lambert Initiative for Cannabinoid Therapeutics, this world-first trial is examining whether the non-intoxicating component of cannabis - cannabidiol (CBD) - is safe and effective in reducing neuropathic pain in people with spinal cord injury.
The trial will be run at Neuroscience Research Australia in Randwick, Sydney, a well-known facility for brain imaging and spinal cord injury research.
"Success of this trial would trailblaze future research on the benefits of CBD in other neuropathic pain conditions which, much like neuropathic pain following spinal cord injury, remain undertreated and misunderstood", said the study's co-investigator Professor Iain McGregor from the University of Sydney's Lambert Initiative for Cannabinoid Therapeutics.
To find out more about the SCAN trial, visit HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 23
